ONWARD Medical Establishes US ADR Program and Begins Trading on OTCQX Best Market
ONWARD Medical (Euronext: ONWD, OTCQX: ONWRY) has established a sponsored Level 1 American Depositary Receipt (ADR) program in the United States through the Bank of New York Mellon (BNY), with ADRs now trading on the OTCQX® Best Market under symbol ONWRY.
The medical technology company, which develops spinal cord stimulation therapies for movement restoration, aims to enhance US investor access through this program. One ONWARD ADR represents one ordinary share and is denominated in US dollars, making it easier for American investors to trade.
The ADR program and OTCQX upgrade are designed to broaden ONWARD's shareholder base and increase stock liquidity. BNY will serve as the depositary bank and transfer agent for the ADR program, with US investors able to access financial disclosure and Real-Time Level 2 quotes on otcmarkets.com.
ONWARD Medical (Euronext: ONWD, OTCQX: ONWRY) ha istituito un programma sponsorizzato di American Depositary Receipt (ADR) di livello 1 negli Stati Uniti tramite la Bank of New York Mellon (BNY), con gli ADR ora quotati sul mercato OTCQX® Best Market con il simbolo ONWRY.
La società di tecnologia medica, che sviluppa terapie di stimolazione del midollo spinale per il recupero del movimento, punta a migliorare l'accesso degli investitori statunitensi attraverso questo programma. Un ADR ONWARD rappresenta un'azione ordinaria ed è denominato in dollari USA, facilitando così le operazioni degli investitori americani.
Il programma ADR e l'upgrade su OTCQX sono pensati per ampliare la base azionaria di ONWARD e aumentare la liquidità delle azioni. BNY fungerà da banca depositaria e agente di trasferimento per il programma ADR, permettendo agli investitori statunitensi di accedere alle informazioni finanziarie e ai prezzi in tempo reale di livello 2 su otcmarkets.com.
ONWARD Medical (Euronext: ONWD, OTCQX: ONWRY) ha establecido un programa patrocinado de American Depositary Receipt (ADR) de Nivel 1 en Estados Unidos a través del Bank of New York Mellon (BNY), con los ADR ahora cotizando en el mercado OTCQX® Best Market bajo el símbolo ONWRY.
La compañía de tecnología médica, que desarrolla terapias de estimulación de la médula espinal para la restauración del movimiento, busca mejorar el acceso de los inversores estadounidenses mediante este programa. Un ADR de ONWARD representa una acción ordinaria y está denominado en dólares estadounidenses, facilitando así la negociación para los inversores americanos.
El programa ADR y la actualización a OTCQX están diseñados para ampliar la base de accionistas de ONWARD y aumentar la liquidez de las acciones. BNY actuará como banco depositario y agente de transferencia para el programa ADR, permitiendo a los inversores estadounidenses acceder a la información financiera y a cotizaciones en tiempo real de nivel 2 en otcmarkets.com.
ONWARD Medical (Euronext: ONWD, OTCQX: ONWRY)는 Bank of New York Mellon(BNY)를 통해 미국에서 스폰서 Level 1 미국예탁증서(ADR) 프로그램을 설립했으며, 현재 OTCQX® Best Market에서 ONWRY 심볼로 거래되고 있습니다.
이 의료기술 회사는 척수 자극 치료법을 개발하여 운동 기능 회복을 목표로 하며, 이번 프로그램을 통해 미국 투자자들의 접근성을 높이고자 합니다. ONWARD ADR 1주는 보통주 1주를 나타내며 미국 달러로 표시되어 미국 투자자들이 쉽게 거래할 수 있습니다.
ADR 프로그램과 OTCQX 업그레이드는 ONWARD의 주주 기반을 확대하고 주식 유동성을 증가시키기 위해 설계되었습니다. BNY는 ADR 프로그램의 예탁은행 및 이전 대리인 역할을 하며, 미국 투자자들은 otcmarkets.com에서 재무 공시 및 실시간 레벨 2 시세를 확인할 수 있습니다.
ONWARD Medical (Euronext : ONWD, OTCQX : ONWRY) a mis en place un programme parrainé de certificats de dépôt américains (ADR) de niveau 1 aux États-Unis via la Bank of New York Mellon (BNY), avec des ADR désormais cotés sur le marché OTCQX® Best Market sous le symbole ONWRY.
Cette entreprise de technologie médicale, qui développe des thérapies de stimulation de la moelle épinière pour la restauration du mouvement, vise à faciliter l'accès des investisseurs américains grâce à ce programme. Un ADR ONWARD représente une action ordinaire et est libellé en dollars américains, ce qui facilite les échanges pour les investisseurs américains.
Le programme ADR et la montée en gamme OTCQX ont pour objectif d'élargir la base d'actionnaires d'ONWARD et d'accroître la liquidité des actions. BNY agira en tant que banque dépositaire et agent de transfert pour le programme ADR, permettant aux investisseurs américains d'accéder aux informations financières et aux cotations en temps réel de niveau 2 sur otcmarkets.com.
ONWARD Medical (Euronext: ONWD, OTCQX: ONWRY) hat in den USA über die Bank of New York Mellon (BNY) ein gesponsertes Level-1 American Depositary Receipt (ADR)-Programm eingerichtet, wobei die ADRs nun unter dem Symbol ONWRY am OTCQX® Best Market gehandelt werden.
Das Medizintechnikunternehmen, das Therapien zur Rückenmarkstimulation zur Wiederherstellung der Bewegungsfähigkeit entwickelt, möchte mit diesem Programm den Zugang für US-Investoren erleichtern. Ein ONWARD ADR entspricht einer Stammaktie und ist in US-Dollar denominiert, was amerikanischen Investoren den Handel erleichtert.
Das ADR-Programm und das OTCQX-Upgrade sollen die Aktionärsbasis von ONWARD erweitern und die Aktienliquidität erhöhen. BNY fungiert als Depotbank und Transferstelle für das ADR-Programm, wobei US-Investoren über otcmarkets.com Zugang zu Finanzberichten und Echtzeit-Level-2-Kursen erhalten.
- Enhanced access to US investor market through OTCQX listing
- Potential increase in stock liquidity
- Broader shareholder base expansion opportunity
- Simplified trading process for US investors through dollar-denominated ADRs
- None.
Sponsored Level 1 ADR program facilitates trading by US investors following recent FDA clearance and commercial launch
BNY will be ADR depositary bank
Ticker symbol for US investors is ONWRY
EINDHOVEN, the Netherlands, April 24, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and OTCQX: ONWRY), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and other movement disabilities, today announces it has established a sponsored Level 1 American Depositary Receipt ("ADR") program in the United States through the Bank of New York Mellon ("BNY"), and its ADRs have begun trading on the OTCQX® Best Market under the symbol ONWRY.
“Establishing an ADR program with BNY facilitates trading by US institutional investors, many of whom have expressed interest in supporting ONWARD but prefer to transact in US dollars and in US traded instruments,” said Dave Marver, CEO of ONWARD Medical. “This ADR program and our new trading platform on OTCQX will make it easier for qualified US institutional and retail investors to participate in our growth.”
“As a market leader in the Depositary Receipts market, having delivered customized and market-driven solutions for issuers, brokers and investors for decades, BNY is pleased to work with ONWARD Medical on the important step to expand its presence in the US market,” said Christopher Kearns, Global Head of Depositary Receipts at BNY.
“We are proud to announce the addition of ONWARD Medical to the OTCQX Market,” said Jason Paltrowitz, EVP of Corporate Services at OTC Markets. “This milestone not only marks a significant achievement for the company but also highlights the interplay between the European capital markets and US investors seeking new investment opportunities.”
The ADR program and accompanying OTCQX upgrade are expected to improve ONWARD's US investor access, with the goal to broaden the Company's shareholder base and increase stock liquidity. An ADR is a negotiable depositary receipt denominated in US dollars and representing ownership of foreign shares in a non-US company. ADRs are specially designed to make it easier for American investors to purchase, hold and sell an US instrument representing non-US securities. BNY acts as the depositary bank and transfer agent for ONWARD’s ADR program and one ONWARD ADR represents one ordinary share.
US investors can find current financial disclosure and Real-Time Level 2 quotes for the Company on www.otcmarkets.com. The Company also expects many of the leading US investor platforms to provide quotes and information, searchable by the ticker ONWRY.
To learn more about ONWARD's commitment to partnering with the Spinal Cord Injury (SCI) Community to develop innovative solutions for restoring movement, function, and independence after spinal cord injury, please visit ONWD.com.
For US investors, visit: https://ir.onwd.com/us-investors-0
To be kept informed about the Company's technologies, research studies, and the availability of therapies in your area, please complete this webform.
About ONWARD Medical
ONWARD Medical is a medical technology company creating therapies to restore movement, function, and independence in people with SCI and other movement disabilities. Building on more than a decade of scientific discovery, preclinical research, and clinical studies conducted at leading hospitals, rehabilitation clinics, and neuroscience laboratories, the Company has developed ARC Therapy, which has been awarded ten Breakthrough Device Designations from the US Food and Drug Administration (FDA). The Company’s ARC-EX System is cleared for commercial sale in the US. In addition, the Company is developing an investigational implantable system called ARC-IM with and without an implanted brain-computer interface (BCI).
Headquartered in the Netherlands, the Company has a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts. The Company is listed on Euronext Paris, Brussels, and Amsterdam (ticker: ONWD) and its US ADRs can be traded on OTCQX (ticker: ONWRY).
For more information, visit ONWD.com and connect with us on LinkedIn and YouTube.
To be kept informed about the Company’s technologies, research studies, and the availability of therapies in your area, please complete this webform.
For Media Inquiries:
media@onwd.com
For Investor Inquiries:
investors@onwd.com
Disclaimer
Certain statements, beliefs, and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, delays in regulatory approvals, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
Trademarks: ONWARD, ARC-EX, ARC-IM, ARC-BCI, and the stylized O-Logo are proprietary and registered trademarks of ONWARD Medical. Unauthorized use is strictly prohibited.
FAQ
What is the significance of ONWARD Medical's ADR program launch on OTCQX (ONWRY)?
How many ONWARD Medical (ONWRY) ordinary shares does one ADR represent?
Where can investors find ONWARD Medical (ONWRY) financial disclosures and quotes?
Who is the depositary bank for ONWARD Medical's ADR program (ONWRY)?
